Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Non-Current Debt (2023 - 2025)

Historic Non-Current Debt for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $5.6 million.

  • BioLineRx's Non-Current Debt fell 6886.33% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 6886.33%. This contributed to the annual value of $9.0 million for FY2024, which is 3515.39% up from last year.
  • As of Q3 2025, BioLineRx's Non-Current Debt stood at $5.6 million, which was down 6886.33% from $6.7 million recorded in Q2 2025.
  • BioLineRx's Non-Current Debt's 5-year high stood at $18.8 million during Q2 2024, with a 5-year trough of $5.6 million in Q3 2025.
  • In the last 3 years, BioLineRx's Non-Current Debt had a median value of $8.2 million in 2023 and averaged $9.4 million.
  • As far as peak fluctuations go, BioLineRx's Non-Current Debt surged by 12118.89% in 2024, and later crashed by 6886.33% in 2025.
  • Over the past 3 years, BioLineRx's Non-Current Debt (Quarter) stood at $6.6 million in 2023, then surged by 35.15% to $9.0 million in 2024, then tumbled by 37.5% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $6.7 million for Q2 2025, and $7.6 million during Q1 2025.